← Back to Search

Herbal Therapy

ArtemiCoffee for Prostate Cancer

Phase 2
Recruiting
Led By Zin Myint, MD
Research Sponsored by Zin W Myint
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Completion of localized therapy (prostatectomy or radiotherapy) for prostate adenocarcinoma (either histologically or cytologically confirmed)
Patients with a prior or concurrent malignancy (non-prostate) whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen as determined by the treating physician are eligible
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks (baseline, 3-mos, 6-mos and post-treatment)
Awards & highlights

Study Summary

This trial will study whether Aa coffee can decrease PSA levels in men with BCR prostate cancer.

Who is the study for?
This trial is for men over 18 who've had prostate cancer treatment but now have rising PSA levels without visible cancer spread. They should be relatively healthy, with no recent hormone therapy or certain other drugs, and no serious illnesses that could affect study participation.Check my eligibility
What is being tested?
The trial tests ArtemiCoffee's ability to lower rising PSA in patients with biochemical recurrence of prostate cancer after initial treatments like surgery or radiation. It explores whether this coffee containing Artesunate can slow down the return of cancer signs.See study design
What are the potential side effects?
While specific side effects are not listed, similar herbal supplements may cause digestive upset, allergic reactions, or interact with other medications. Participants will be monitored for any adverse effects during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have completed treatment for prostate cancer through surgery or radiation.
Select...
I have another cancer type, but it won't affect this treatment's safety or results.
Select...
I am capable of limited self-care and spend less than half of my day in bed.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks (baseline, 3-mos, 6-mos and post-treatment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks (baseline, 3-mos, 6-mos and post-treatment) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients who achieve a 50% decline in PSA levels
Secondary outcome measures
Change in PSA velocity and slope from pre-treatment to post-treatment
Percentage change in serial PSA
Percentage change in serial testosterone levels
Other outcome measures
Change in plasma concentration of artemisinin and dihydroartemisinin

Trial Design

1Treatment groups
Experimental Treatment
Group I: Prostate cancer patientsExperimental Treatment1 Intervention
Men with biochemical recurrence of prostate cancer after initial local therapy.

Find a Location

Who is running the clinical trial?

Zin W MyintLead Sponsor
2 Previous Clinical Trials
85 Total Patients Enrolled
2 Trials studying Prostate Cancer
85 Patients Enrolled for Prostate Cancer
ArtemiLifeUNKNOWN
1 Previous Clinical Trials
18 Total Patients Enrolled
Zin Myint, MDPrincipal InvestigatorUniversity of Kentucky

Media Library

ArtemiCoffee (Herbal Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05478239 — Phase 2
Prostate Cancer Research Study Groups: Prostate cancer patients
Prostate Cancer Clinical Trial 2023: ArtemiCoffee Highlights & Side Effects. Trial Name: NCT05478239 — Phase 2
ArtemiCoffee (Herbal Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05478239 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this scientific experiment still open?

"The records hosted on clinicaltrials.gov reveal that this medical trial has stopped recruiting participants as of July 25th 2022, despite being initially posted a few months prior in November 1st 2022. However, there are over 1300 other trials actively looking for volunteers at the present moment."

Answered by AI

Has the United States Food and Drug Administration authorized ArtemiCoffee?

"The safety of ArtemiCoffee has been rated 2 on our 1-3 scale since there is prior evidence confirming its security, yet no data indicating it's efficacy."

Answered by AI
~20 spots leftby Dec 2025